In March, 2020, Window Therapeutics in conjunction with the Johnson Lab at The Massachusetts Institute of Technology was awarded the prestigious Assay Cascade Grant, for its Window-Bortezomib program for Multiple Myeloma, from the Nanotechnology Characterization Laboratory (NCL), a division of the National Cancer Institute and the Frederick National Laboratory for Cancer Research. The NCL accepts the most promising cancer nanomedicine candidates into its Assay Cascade characterization and testing program.
Nanomedicines accepted into the program undergo a rigorous evaluation ranging from sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety, efficacy and pharmacokinetics. The studies are tailored to each individual nanomedicine and are designed to promote the clinical translation of these novel therapies. All studies are conducted free of charge for Awardees. Initiation of the evaluation of the Window-Bortezomib program began in the first half of 2021 with developmental research currently in progress.
Cascade Award for Lead Drug Program Development
